Stefania Cuzzubbo
Overview
Explore the profile of Stefania Cuzzubbo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1963
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kacimi S, Dehais C, Feuvret L, Chinot O, Carpentier C, Bronnimann C, et al.
J Clin Oncol
. 2024 Oct;
43(3):329-338.
PMID: 39356975
Purpose: Patients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3) benefit from adding alkylating agent chemotherapy to radiotherapy (RT). However, the optimal chemotherapy regimen between procarbazine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), and vincristine (PCV)...
2.
Picca A, Touat M, Belin L, Gourmelon C, Harlay V, Cuzzubbo S, et al.
Eur J Cancer
. 2024 Mar;
202:114034.
PMID: 38537315
Background: Novel effective treatments are needed for recurrent IDH mutant high-grade gliomas (IDHm HGGs). The aim of the multicentric, single-arm, phase II REVOLUMAB trial (NCT03925246) was to assess the efficacy...
3.
Benusiglio P, Elder F, Touat M, Perrier A, Sanson M, Colas C, et al.
JCO Precis Oncol
. 2023 Jun;
7:e2200525.
PMID: 37262394
Purpose: The Lynch syndrome (LS)-glioma association is poorly documented. As for mismatch repair deficiency (MMRd) in glioma, a hallmark of LS-associated tumors, there are only limited data available. We determined...
4.
Cuzzubbo S, Roch B, Darrasse-Jeze G, Hosten B, Leclercq M, Vignal N, et al.
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36499300
We previously reported that a novel peptide vaccine platform, based on synthetic melanin nanoaggregates, triggers strong cytotoxic immune responses and significantly suppresses tumor growth in mice. However, the mechanisms underlying...
5.
Cuzzubbo S, Carpentier A
Curr Opin Neurol
. 2022 Oct;
35(6):814-822.
PMID: 36226705
Purpose Of Review: We review the recent advances in neurological toxicities of immune checkpoint inhibitors, with a focus on underlying pathophysiologic mechanisms and the implications on their therapeutical management. Recent...
6.
Ursu R, Maillet D, Belin C, Moroni C, Cuzzubbo S, Vernier V, et al.
Neurology
. 2022 Jul;
99(12):511-515.
PMID: 35851255
Objectives: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a promising treatment in relapsing B-cell lymphoma but is frequently associated with acute neurotoxicity. Neurologic long-term safety has not been thoroughly...
7.
Maillet D, Belin C, Moroni C, Cuzzubbo S, Ursu R, Sirven-Villaros L, et al.
Neuro Oncol
. 2021 Apr;
23(9):1569-1575.
PMID: 33822183
Background: Chimeric antigen receptor-modified T (CAR T) cells are profoundly changing the standard of care in B-cell malignancies. This new therapeutic class induces a significant number of acute neurotoxicity, but...
8.
Cuzzubbo S, Carpentier A
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33806772
Thanks to the growing knowledge about cancers and their interactions with the immune system, a huge number of therapeutic cancer vaccines have been developed in the past two decades. Despite...
9.
Cuzzubbo S, Mangsbo S, Nagarajan D, Habra K, Pockley A, McArdle S
Front Immunol
. 2021 Mar;
11:615240.
PMID: 33679703
Although the discovery and characterization of multiple tumor antigens have sparked the development of many antigen/derived cancer vaccines, many are poorly immunogenic and thus, lack clinical efficacy. Adjuvants are therefore...
10.
Cluzeau T, Sebert M, Rahme R, Cuzzubbo S, Lehmann-Che J, Madelaine I, et al.
J Clin Oncol
. 2021 Feb;
39(14):1575-1583.
PMID: 33600210
Purpose: -mutated () myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) have very poor outcome irrespective of the treatment received, including 40% responses (20% complete remission [CR]) with azacitidine (AZA)...